FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
|Articles|January 2, 2019
- Pharmaceutical Technology-01-02-2019
- Volume 43
- Issue 1
Electrical Position Indicator for Linear Actuators
GEMÜ’s 1205 electrical position indicator is suitable for demanding applications in category 2, zone 1, and/or zone 21 ATEX areas, as well as for robust use at low temperatures down to -20 °C.
GEMÜ’s 1205 electrical position indicator is suitable for demanding applications in category 2, zone 1, and/or zone 21 “atmosphères explosibles” or equipment for potentially explosive atmospheres (ATEX) areas, as well as for robust use at low temperatures down to -20 °C.
The indicator has an aluminum flameproof enclosure and an ‘increased safety’ ignition protection type, with all interior movable components intended for a long mechanical life, the company reports. Additionally, the indicator has continuously adjustable microswitches for recording end positions with which the closed and/or open position can be reliably recorded with a valve stroke of 2–70 mm.
Articles in this issue
over 7 years ago
Packaging Peril: ‘No-Deal’ Brexit May Lead to Missed Deadlinealmost 8 years ago
Looking Beyond the Deadlinealmost 8 years ago
Great Expectationsalmost 8 years ago
Smarter Packaging Comes to the Pharma Marketalmost 8 years ago
Continuous Processing: Challenges and Opportunities of Virus Filtrationalmost 8 years ago
Improved Mixer Lift and Seal Designsalmost 8 years ago
Tabletop Spray Dryeralmost 8 years ago
Microplate Spectrophotometeralmost 8 years ago
FDA Marks Record Year for New Drug Approvalsalmost 8 years ago
Internal and External Challenges to Pharma in 2019Related to this article
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Trending on Pharmaceutical Technology
1
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
Sustainability in Healthcare Packaging: The Journey From Yesterday to Tomorrow
5